New #JITC commentary: Commentary on differential impact of TIM-3 ligands on NK cell function

New #JITC article: Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915 @ProfGLongMIA.@MelanomaAus

New #JITC commentary: Shared epitopes create safety and efficacy concerns in several cancer vaccines

New #JITC article: Enhancing outcomes in medically inoperable early-stage NSCLC with gut-targeted antibiotics and stereotactic body radiotherapy: results from a randomized pilot study @tquarton @NASAAmes

New #JITC letter: Correspondence on “METTL3 promotes an immunosuppressive microenvironment in bladder cancer via m6A-dependent CXCL5/CCL5 regulation” by Tong et al

New #JITC article: Malevolent alliance of MYBL2hi cancer stem cell and SPP1+ macrophage confers resistance to neoadjuvant immunotherapy in bladder cancer.

New #JITC review: Therapeutic potential of targeting LAG-3 in cancer @diwakardavar @UPMCHillmanCC

New #JITC article: Gene-expression signature predicts autoimmune toxicity in metastatic melanoma @MargaretOttavi1 @paolochiodini

New #JITC letter: Authors response to “Letter to the Editor”: “Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types” @RyonGraf @drgandara @FoundationATCG

New #JITC article: Oncolytic HSV-IL27 expression improves CD8 T cell function and therapeutic activity in syngeneic glioma models @lexaamartin @Ilse_Hernandez1

New #JITC article: Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy.@TobiasBexte @MartMichaelis

New #JITC article: ADI-270: an armored allogeneic gamma delta T cell therapy designed to target CD70-expressing solid and hematologic malignancies.@blake_aftab @AdicetBio

New #JITC article: Enhanced antitumor immunity of VNP20009-CCL2-CXCL9 via the cGAS/STING axis in osteosarcoma lung metastasis

New #JITC article: Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort @youngkwangchae @anup_kasi @walshauserMD @EdgarEGK @Dra_Cells @EladSharonMD

New #JITC article: Low-dose radiotherapy enhances the efficacy of PD-L1 blockade and induces the abscopal effect @Edradonc @GustaveRoussy.@Inserm

New #JITC article: Immunotherapy for rapid bone marrow conditioning and leukemia depletion that allows efficient hematopoietic stem cell transplantation

New #JITC article: Targeting Annexin A2 to reactivate tumor-associated antigens presentation and relieve immune tolerance in liver cancer

New #JITC article: Mapping immune activity in HPV-negative head and neck squamous cell carcinoma: a spatial multiomics analysis

New #JITC hypothesis: Systematic identification and targeting of master regulator checkpoints (MRC) governing tumor microenvironment-mediated immune evasion.@BaboRebelo @idibaps

New #JITC position article and guidelines: SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy @RobertFerrisMD.@lab_kok @evanlipson @MarcoRuella @MarkYarchoan